2019.11 | Passed PMDA audit (Gadoteridol, Iopamidol) |
---|---|
2019.04 | DOTA DMF |
2018.06 | Cilastatin Na DMF |
2017.08 | Gadobutrol monohydratel(MRI contrast agent API) DMF |
2017.08 | Establishment of DongKook Lifescience |
2017.02 | Passed PMDA audit (Gadopentetate monomeglumine) |
2015.12 | Acquired Certificate of GMP Compliance of a Manufacturer (MFDS) |
2013.12 | Developed Gadoteridol (MRI contrast agent API) |
2009.10 | Developed DOTA(MRI contrast agent API) |
2007.12 | Registered Gadopentetate monomeglumine(API) to PMDA (219MF10351) |
2007.04 | Approved aseptic process of GMP (Cilastatin Na) |
2006.06 | Developed Gadodiamide(MRI contrast agent API) |
2005.06 | Developed Gadopentetate monomeglumine (MRI contrast agent API) |
2002.07 | Developed Iohexol(X-ray contrast agent API) |
2001.07 | Acquired BGMP certificate (KFDA) |
2000.06 | Acquired EU CEP certificate (Iopamidol) |
1999.12 | Developed Iopamidol(X-ray contrast agent API) |
1995.09 | Establishment of DongKook Fine-chemical |
Product(API) | Category |
---|---|
Iopamidol | CT contrast agent |
Gadobutrol monohydrate | MRI contrast agent |
Gadoteridol | MRI contrast agent |
DOTA | MRI contrast agent |
Cilastatin Na | Antibiotic API |